Patents Assigned to Her Majesty the Queen in right of Canada, as represented by the Minister of Health
  • Patent number: 6676285
    Abstract: A mixing device for low speed precision mixing of contents of a vessel has a support member adapted to be rotatably supported in spaced relationship from a bottom portion of the vessel and separated therefrom by a gap, and a brush assembly depending from the support member for sliding engagement with the bottom portion of the vessel. Low speed rotation of the support member within the vessel causes the brush assembly to sweep the bottom portion of the vessel while mixing the contents of the vessel. The brush assembly can be made of a resilient coil or a plurality of filamentary or lamellar elements, affixed to the support member. This device provides controlled and repeatable mixing and is well suited for use in drug dissolution measurement apparatuses used for assessing drug release characteristics of solid oral pharmaceutical products.
    Type: Grant
    Filed: March 19, 2002
    Date of Patent: January 13, 2004
    Assignee: Her Majesty the Queen in right of Canada, as represented by the Minister of Health
    Inventor: Saeed A. Qureshi
  • Publication number: 20030235110
    Abstract: In a method for reproducible dissolution of a pharmaceutical product in a dissolution medium contained within a vessel, a flow regime characterized by high turbidity and low bulk movement of dissolution medium is induced within the vessel. Simultaneously, solid particles of the pharmaceutical product on a bottom portion of the vessel are mechanically dispersed. Induction of the flow regime and mechanical dispersion of solid particles may be accomplished by a brush body adapted to sweep a bottom portion of the vessel. The brush body is repeatably biased into contact with the bottom portion of the vessel, and caused to rotate in a controlled manner.
    Type: Application
    Filed: June 30, 2003
    Publication date: December 25, 2003
    Applicant: Her Majesty the Queen in right of Canada, as represented by The Minister of Health
    Inventor: Saeed A. Qureshi
  • Patent number: 6649743
    Abstract: The identification and characterization of risk factors and their molecular implications in the pathophysiology of human diseases such as cancer is essential for designing efficient diagnostic assays and therapeutic compounds. Estrogenic steroids, under normal physiological conditions, have been shown to play a critical function in several tissues. The response of such a variety of tissues to estrogen stimulation can explain in part its active role in the development and progression of different human diseases, particularly Breast Cancer. Searching for estrogen-responding cellular factors in parental cells of primary human breast carcinomas obtained from tumor biopsies an isoenzyme of putative Leucine Aminopeptidase (LAPase; EC 3.4.11.1) was idenditifed. Results have demonstrated that this marker is found to be elevated in the sera of women with invasive ductal and metastatic carcinomas. A monoclonal antibody against this cellular marker have been produced.
    Type: Grant
    Filed: March 30, 2000
    Date of Patent: November 18, 2003
    Assignee: Her Majesty the Queen in right of Canada, as represented by the Minister of Health
    Inventor: Gabriel Pulido-Cejudo
  • Publication number: 20030058735
    Abstract: A mixing device for low speed precision mixing of contents of a vessel has a support member adapted to be rotatably supported in spaced relationship from a bottom portion of the vessel and separated therefrom by a gap, and a brush assembly depending from the support member for sliding engagement with the bottom portion of the vessel. Low speed rotation of the support member within the vessel causes the brush assembly to sweep the bottom portion of the vessel while mixing the contents of the vessel. The brush assembly can be made of a resilient coil or a plurality of filamentary or lamellar elements, affixed to the support member. This device provides controlled and repeatable mixing and is well suited for use in drug dissolution measurement apparatuses used for assessing drug release characteristics of solid oral pharmaceutical products.
    Type: Application
    Filed: March 19, 2002
    Publication date: March 27, 2003
    Applicant: Her Majesty the Queen in Right of Canada, as Represented by The Minister of Health
    Inventor: Saeed A. Qureshi
  • Patent number: 6521415
    Abstract: The identification and characterization of risk factors and their molecular implications in the pathophysiology of human diseases such as cancer is essential for designing efficient diagnostic assays and therapeutic compounds. Estrogenic steroids, under normal physiological conditions, have been shown to play a critical function in several tissues. The response of such a variety of tissues to estrogen stimulation can explain in part its active role in the development and progression of different human diseases, particularly breast cancer. Searching for estrogen-responding cellular factors in parental cells of primary human breast carcinomas obtained from tumour biopsies, two cellular markers, an isoenzyme of putative leucine aminopeptidase (LAPase; EC 3.4.11.1) from parental cells of primary human breast carcinomas obtained from tumour biopsies, and cytosolic NDP-Kinase/Nm23 (EC 2.7.4.6) from HL60 cells were identified. Monoclonal antibodies against each cellular marker have been produced.
    Type: Grant
    Filed: March 30, 2000
    Date of Patent: February 18, 2003
    Assignees: Canbreal Therodiagnostics Canada Holding Corporation, Her Majesty the Queen in right of Canada, as represented by the Minister of Health
    Inventor: Gabriel Pulido-Cejudo
  • Patent number: 6406701
    Abstract: In spite of having achieved an in depth and comprehensive genetic structure of the human immunodeficiency virus (HIV) and of that of its several structural and geographical clusters, a very limited success in the prevention and treatment of AIDS has been attained. Described herein is a method for preventing or reducing HIV infectivity by using an antibody specific for estrogen-stimulated leucine aminopeptidase (es-LAPase), or one or more inhibitors of LAPase activity, or a combination thereof. Also described is a method for preventing or reducing HIV infectivity by using an antibody specific for es-LAPase, one or more inhibitors of es-LAPase activity and an anti-estrogen compound. The novel compositions are also defined.
    Type: Grant
    Filed: March 30, 2000
    Date of Patent: June 18, 2002
    Assignees: Canbreal Therodiagnostics Canada Holding Corporation, Her Majesty the Queen in right of Canada as represented by the Minister of Health
    Inventor: Gabriel Pulido-Cejudo
  • Patent number: 6171789
    Abstract: A novel IS (insertion sequence) element characteristic of a virulent isolate (ET12/cblA isolate) of Burkholderia cepacia. The IS element is a hybrid of two other IS elements commonly found in isolates of B. cepacia, namely IS402 [SEQ ID NO:2] and IS1356 [SEQ ID NO:3]. The IS hybrid IS element has the sequence shown in the Figure [SEQ ID NO:1]. The fact that the hybrid IS element is characteristic of the virulent isolate means that it can be used as an indicator of that isolate. Thus, the invention includes a method of testing for an ET12/cblA isolate of B. cepacia by testing a sample for the presence of the hybrid IS element, eg. by amplification of the IS element by PCR and identification of the amplified sequence.
    Type: Grant
    Filed: April 24, 1998
    Date of Patent: January 9, 2001
    Assignee: Her Majesty the Queen in right of Canada, as represented by the Minister of Health
    Inventors: Wendy M. Johnson, Shaun D. Tyler, Kenneth R. Rozee
  • Patent number: 5626130
    Abstract: An apparatus for exposing laboratory animals to test substances comprises, generally, at least two supply manifolds for supplying each a gaseous or a vaporous substance, an exhaust manifold for removing an exhalate of said animals and unused portion of said test substance, and a plurality of inhalation chambers. Each chamber is dimensioned to accommodate a nasal part of the animal's head and is in fluid communication with the at least two supply manifolds and with the exhaust manifold. The apparatus is designed to prevent the streams of test substances hitting the animal's nostrils and causing an avoidance reaction.
    Type: Grant
    Filed: November 22, 1995
    Date of Patent: May 6, 1997
    Assignee: Her Majesty the Queen in right of Canada, as represented by the Minister of Health
    Inventors: Renaud Vincent, Josee Guenette
  • Patent number: 5597735
    Abstract: A Dot-Blot assay ("spot test") with Bis-N,N,dioctadecylamide (BDA.TDA) as antigen was developed to detect anti-BDA.TDA antibodies in tuberculosis patients. To develop the antigen-antibody reaction, as a first step and in order to enhance the reaction, an anti-human rabbit serum was used followed by incubation with a protein A-colloidal gold conjugate. This assay showed almost equal sensitivity and specificity as the .beta.-galactosidase ELISA test which was conducted in parallel. This simple and fast assay could be used in places where ELISA equipment is not easily available.
    Type: Grant
    Filed: September 2, 1994
    Date of Patent: January 28, 1997
    Assignee: Her Majesty the Queen in right of Canada, as represented by the Minister of Health and Welfare
    Inventors: Adalbert Laszlo, Vera Handzel, Lucio Vera-Cabrera
  • Patent number: 5554537
    Abstract: A sampler for determining the microbiological safety or hygienic quality of surfaces comprising a scrubber-retainer which comprises a compressible liquid absorbing elastic element for scrubbing a test surface and releasably retaining a liquid, and a surrounding chamber to confine a region around the scrubber-retainer against the sample surface. The sampler includes a drive mechanism for moving the scrubber-retainer to scrub the test surface and release analytes from the test surface, and alternately compressing and decompressing the compressible material to allow liquid to be alternately released and absorbed, respectively, to produce a suspension of the released analytes.
    Type: Grant
    Filed: November 29, 1995
    Date of Patent: September 10, 1996
    Assignee: Her Majesty the Queen in right of Canada as represented by the Minister of Health and Welfare Canada
    Inventor: Anthony N. Sharpe
  • Patent number: 5503992
    Abstract: Murine monoclonal antibodies directed against a novel outer membrane protein (OMP) of Haemophilus influenzae have been isolated and characterized. The gene encoding of the outer membrane protein has also been isolated and characterized. Portions of the DNA sequence of the 15 kD OMP gene are useful as probes to diagnose the presence of Haemophilus influenzae in samples. These DNA's also make available polypeptide sequences of immunoreactive epitopes encoded within the gene, thus permitting the production of polypeptides which are useful as standards or reagents in diagnostic tests and/or as components of vaccines. Monoclonal antibodies directed against epitopes of the 15 kD OMP are also useful for diagnostic tests and as therapeutic agents for passive immunization.
    Type: Grant
    Filed: September 7, 1993
    Date of Patent: April 2, 1996
    Assignees: Washington University, Her Majesty the Queen in right of Canada, as represented by the Minister of Health and Welfare Canada
    Inventors: Bernard R. Brodeur, Josee Hamel, Robert S. Munson, Jr., Susan Grass
  • Patent number: 5344759
    Abstract: A method of testing for tuberculosis and leprosy in animals or humans and antigens used in the method. The method involves carrying out an assay on sera from humans or animals using an antigen to bind antibodies in sera. The antigens used in the method are synthetic pseudo cord factor-like glycolipids having the structures (I) or (II) below: ##STR1## wherein R represents a straight or branched chain alkyl group having 15 to 18 carbon atoms. The antigens can be produced by chemical synthesis, and can therefore be made available in suitable quantities, and are relatively stable at ambient temperatures while showing good sensitivity and specificity for tuberculosis and leprosy. The antigens can be used, for example, for enzyme-linked immunosorbent assays, and related "spot tests" for diagnosing tuberculosis and leprosy.
    Type: Grant
    Filed: May 11, 1992
    Date of Patent: September 6, 1994
    Assignee: Her Majesty the Queen in right of Canada, as represented by the Minister of Health & Welfare
    Inventors: Adalbert Laszlo, Vera Handzel
  • Patent number: 4619483
    Abstract: An adaptation for a chair for the physically handicapped comprises a special shoulder support arrangement which is connected to the back of the chair. A headrest is provided on the shoulder support and overlaps a portion of the back. A recess is defined below the headrest and along the shoulder support to receive and support a shoulder of a person sitting on the chair supporting their lean to that side. The headrest is mounted on the shoulder support in a manner to provide for vertical height adjustment of the headrest relative to the seat to accommodate varying shoulder heights of persons using the chair. This type of adaptation encourages the physically handicapped to use their own muscles to sit up in the chair. The attachment is particularly suitable to people who are suffering from deteriorating muscular conditions as well as victims of organic brain syndromes such as Alzheimer's disease.
    Type: Grant
    Filed: October 1, 1984
    Date of Patent: October 28, 1986
    Assignee: Her Majesty the Queen in right of Canada, as represented by the Minister of Health
    Inventors: Donna J. Dickey, Sebastian Dobler, Natalie Horejda